Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association.

Creator(s)

Connie B. Newman
David Preiss
Jonathan A. Tobert
Terry A. Jacobson
Robert L. Page
Larry B. Goldstein
Clifford Chin
Lisa R. Tannock
Michael Miller
Geetha Raghuveer, Children's Mercy HospitalFollow
P Barton Duell
Eliot A. Brinton
Amy Pollak
Lynne T. Braun
Francine K. Welty
American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council

Document Type

Article

Publication Date

2-2019

Identifier

DOI: 10.1161/ATV.0000000000000073

Abstract

One in 4 Americans >40 years of age takes a statin to reduce the risk of myocardial infarction, ischemic stroke, and other complications of atherosclerotic disease. The most effective statins produce a mean reduction in low-density lipoprotein cholesterol of 55% to 60% at the maximum dosage, and 6 of the 7 marketed statins are available in generic form, which makes them affordable for most patients. Primarily using data from randomized controlled trials, supplemented with observational data where necessary, this scientific statement provides a comprehensive review of statin safety and tolerability. The review covers the general patient population, as well as demographic subgroups, including the elderly, children, pregnant women, East Asians, and patients with specific conditions such as chronic disease of the kidney and liver, human immunodeficiency viral infection, and organ transplants. The risk of statin-induced serious muscle injury, including rhabdomyolysis, is

Journal Title

Arteriosclerosis, thrombosis, and vascular biology

Volume

39

Issue

2

First Page

38

Last Page

81

MeSH Keywords

American Heart Association; Cerebral Hemorrhage; Diabetes Mellitus; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver; Muscular Diseases; Randomized Controlled Trials as Topic; Rhabdomyolysis; United States

Keywords

AHA Scientific Statements; cognitive function; diabetes; drug interactions; erectile dysfunction; hemorrhagic stroke; muscle; nocebo; statin intolerance; statin safety

Comments

Erratum in

• Correction to: Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. [No authors listed]Arterioscler Thromb Vasc Biol. 2019 May;39(5):e158. doi: 10.1161/ATV.0000000000000081.PMID: 31017821 No abstract available.

Recommended Citation

Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association [published correction appears in Arterioscler Thromb Vasc Biol. 2019 May;39(5):e158]. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-e81. doi:10.1161/ATV.0000000000000073